EUVIMEDScopri EUVIMED
Open access · CC BY 4.0

Development of the Novel FLOX Score to Assess Risk of Intubation in Children With Immunocompromising Conditions Receiving High Flow Nasal Cannula

Michelle A Mai iD, Colin M Rogerson iD, Courtney M Rowan iD

Pediatric Pulmonology · 2026

DOI: 10.1002/ppul.71814 ↗

At a glance

Journal article in Pediatric Pulmonology, 2026. Written by Michelle A Mai and 2 co-authors. Institution: Indiana University School of Medicine, Indianapolis, Indiana, USA. Major MEDLINE topics: Cannula, Immunocompromised Host, Intubation, Intratracheal, Oxygen Inhalation Therapy. 21 references. The full text is freely available (open access, CC BY 4.0). Funded by: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Heated, humidified, high‐flow nasal cannula (HFNC) before intubation has been associated with increased mortality in children with immunocompromising conditions (ICC).

Objectives

We sought to describe HFNC failure (intubation) rate and aimed to develop a novel score associated with HFNC failure.

Methods

This is a single center, retrospective cohort. Patients (aged 0–26 years) with ICCs who used HFNC between 2021 and 2023 were included.

Results

Forty‐four (47.3%) of 93 included subjects failed HFNC. PICU mortality was 14% ( n = 13). The median duration of HFNC was 18.7 h (IQR: 6.0, 40.4). We developed the novel FLOX ((flow in Liters/minute)/weight (kg)*FiO 2 ) score. Median FLOX score was higher with HFNC failure at initiation ( p = 0.04), 2 h ( p = 0.03), 4 h ( p = 0.05), and 6 h ( p = 0.05). Adjusting for acuity, the odds of HFNC failure with a FLOX score (≥0.20) were as follows: Initiation OR = 2.5 (95%CI: 1.03, 5.9), p = 0.042); 2 h of HFNC, OR = 4.3 ((95%CI: 1.7, 10.9), p = 0.002); 4 h of HFNC, OR = 6.5 (95%CI: 2.5, 16.8), ( p < 0.001); and 6 h of HFNC, OR = 4.9 (95%CI: 1.9, 12.7), ( p = 0.001).

Conclusion

In children with ICCs, almost half fail HFNC. Mortality was high in those who fail HFNC. The FLOX score, specifically a FLOX ≥ 0.20 is associated with increased odds of failing HFNC in our ICC cohort.

Subjects

MeSH terms (MEDLINE)

CannulaImmunocompromised HostIntubation, IntratrachealOxygen Inhalation TherapyRespiratory InsufficiencyNoninvasive VentilationHumansRetrospective StudiesInfantChildFemaleMaleChild, PreschoolAdolescentYoung AdultRisk AssessmentInfant, NewbornIntensive Care Units, Pediatric

Author keywords

Immunocompromised hostNoninvasive ventilationcancercritical carepediatricsrespiratory distress syndromerespiratory insufficiency

Authors and institutions

  • Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Department of Pediatrics, Division of Critical Care, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Riley Hospital for Children at IU Health, Indianapolis, Indiana, USA.
  • Regenstrief Center for Biomedical Informatics, Indianapolis, Indiana, USA.

ORCID profiles: Michelle A Mai, Colin M Rogerson, Courtney M Rowan

Funding

  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute

Cite

APA

Mai, M. A., Rogerson, C. M., & Rowan, C. M. (2026). Development of the Novel FLOX Score to Assess Risk of Intubation in Children With Immunocompromising Conditions Receiving High Flow Nasal Cannula. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71814

Vancouver

Mai MA, Rogerson CM, Rowan CM. Development of the Novel FLOX Score to Assess Risk of Intubation in Children With Immunocompromising Conditions Receiving High Flow Nasal Cannula. Pediatric Pulmonology. 2026. doi:10.1002/ppul.71814

BibTeX
@article{Mai2026,
  author = {Mai, Michelle A and Rogerson, Colin M and Rowan, Courtney M},
  title = {Development of the Novel FLOX Score to Assess Risk of Intubation in Children With Immunocompromising Conditions Receiving High Flow Nasal Cannula},
  journal = {Pediatric Pulmonology},
  year = {2026},
  doi = {10.1002/ppul.71814}
}
Start for free →